Abingworth
Natalie Mount is an accomplished professional with extensive experience in the biotechnology and pharmaceutical sectors, currently serving as a Venture Partner at Abingworth and Board Chair at Wugen since August 2022. Natalie holds the position of Independent Board Director at Rinri Therapeutics since January 2020. Previously, Natalie was the Chief Executive Officer of Adaptate Biotherapeutics from its inception until its acquisition by Takeda in June 2022, and served as an Independent Board Director at GenSight Biologics from April 2017 to April 2021. Natalie's earlier roles include Chief Scientific Officer at GammaDelta Therapeutics and Chief Clinical Officer at the Cell and Gene Therapy Catapult, contributing significantly to the advancement of cell-based therapies. Natalie's career also includes leadership positions at Pfizer, where responsibilities encompassed clinical development in regenerative medicine and women's health. Natalie earned a PhD in Biochemistry from UCL and holds a degree in Natural Sciences from the University of Cambridge.
This person is not in any teams
This person is not in any offices
Abingworth
1 followers
Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciences sectors. Supporting its portfolio companies with a team of 25 at offices in London, Menlo Park, and Boston, Abingworth has invested in 151 life science companies, completed 65 IPOs and 42 mergers and acquisitions.